Startseite Medizin Giant plurihormonal pituitary adenoma in a child – case study
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Giant plurihormonal pituitary adenoma in a child – case study

  • Elżbieta Moszczyńska ORCID logo , Wiesława Grajkowska ORCID logo , Maria Maksymowicz ORCID logo , Joanna Malicka ORCID logo , Mieczysław Szalecki ORCID logo und Monika Prokop-Piotrkowska ORCID logo EMAIL logo
Veröffentlicht/Copyright: 21. Juli 2021

Abstract

Objectives

To describe the case of a 12-year-old girl with a rare plurihormonal pituitary macroadenoma secreting prolactin (PRL), growth hormone (GH), thyroid-stimulating hormone (TSH), and alpha subunit (α-SU).

Case presentation

The patient experienced recurrent headaches and progressing loss of vision in one eye. During the examination, abnormalities such as tall stature, coarse facial features, enlarged feet and hands, tachycardia, hand tremor, hyperhidrosis, galactorrhea, and goiter were observed. Head magnetic resonance imaging (MRI) revealed a solid tumor in the anterior and middle cranial fossa, measuring 80 × 50 × 55 mm. A stereotactic biopsy revealed plurihormonal Pit-1 positive pituitary adenoma secreting PRL, GH, and TSH. A pituitary hyperfunction with PRL, GH, TSH, and α-SU excess was diagnosed. The patient was successfully treated pharmacologically with dopamine agonists and somatostatin analogue, and a decrease of tumor volume (30%) was achieved.

Conclusions

When neurosurgery is not possible, long-term pharmacological treatment of plurihormonal pituitary macroadenoma can be a safe and relatively effective alternative.


Corresponding author: Monika Prokop-Piotrkowska, MD, Department of Endocrinology and Diabetology, Children’s Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  3. Competing interests: The authors declare no conflict of interests.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: We hereby state that the subject and her parent gave their written informed consent to publish their cases.

References

1. Keil, MF, Stratakis, CA. Pituitary tumors in childhood: an update in their diagnosis, treatment and molecular genetics. Expert Rev Neurother 2008;8:563–74. https://doi.org/10.1586/14737175.8.4.563.Suche in Google Scholar PubMed PubMed Central

2. Gulbadin, D, Li, Z, Shahbaz, M, Farhaj, Z, Shabbir, A, Qi, Q, et al.. Patients with true mixed growth hormone and prolactin-secreting pituitary adenoma: a case series of 12 patients. Br J Neurosurg 2020;34:154–60. https://doi.org/10.1080/02688697.2020.1713989.Suche in Google Scholar PubMed

3. Beatriz, M, Lopes, S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 2017;134:521–35.10.1007/s00401-017-1769-8Suche in Google Scholar PubMed

4. De Menis, E, Visentin, A, Billeci, D, Tramontin, P, Agostini, S, Marton, E, et al.. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest 2001;24:92–7. https://doi.org/10.1007/BF03343820.Suche in Google Scholar PubMed

5. Perry, A, Graffeo, CS, Marcellino, C, Pollock, BE, Wetjen, NM, Meyer, FB. Pediatric pituitary adenoma: case series, review of the literature, and a skull base treatment paradigm. J Neurol Surg Part B Skull Base 2018;79:91–114. https://doi.org/10.1055/s-0038-1625984.Suche in Google Scholar PubMed PubMed Central

6. Asa, SL, Casar-Borota, O, Chanson, P, Delgrange, E, Earls, P, Ezzat, S, et al.. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Canc 2017;24:C5–8. https://doi.org/10.1530/ERC-17-0004.Suche in Google Scholar PubMed

7. Ho, K, Fleseriu, M, Kaiser, U, Salvatori, M, Brue, T, Lopes, MB, et al.. Pituitary neoplasm nomenclature workshop: does adenoma stand the test of time? J Endocr Soc 2021;5:bvaa205. https://doi.org/10.1210/jendso/bvaa205.Suche in Google Scholar PubMed PubMed Central

8. Dyer, EH, Civit, T, Viscot, A, Delalande, O, Derome, P. Transfenoidal surgery for pituitary adenomas in children. Neurosurgery 1994;34:201–12.10.1097/00006123-199402000-00001Suche in Google Scholar

9. Capozzi, A, Scambia, G, Pontecorvi, A, Lello, S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol 2015;31:506–10. https://doi.org/10.3109/09513590.2015.1017810.Suche in Google Scholar PubMed

10. Sethi, A, Didi, M, Dharmaraj, P, Ramakrishnan, R, Senniappan, S, Das, U, et al.. Obesity is common at diagnosis of childhood pituitary adenoma and may persist following successful treatment. Clin Endocrinol (Oxf) 2020;92:323–30. https://doi.org/10.1111/cen.14146.Suche in Google Scholar PubMed

11. Dos Santos Silva, CM, Barbosa, FRP, Lima, GAB, Warszawski, L, Fontes, R, Domingues, RC, et al.. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011;19:800–5. https://doi.org/10.1038/oby.2010.150.Suche in Google Scholar PubMed

12. Daly, AF, Tichomirowa, MA, Beckers, A. Genetic, molecular and clinical features of familial isolated pituitary adenomas. Horm Res 2009;71:116–22. https://doi.org/10.1159/000192448.Suche in Google Scholar PubMed

Received: 2021-03-19
Accepted: 2021-06-29
Published Online: 2021-07-21
Published in Print: 2021-11-25

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Review Article
  3. An endocrine perspective on menstrual suppression for adolescents: achieving good suppression while optimizing bone health
  4. Original Articles
  5. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg)
  6. Evaluation of the resilience of the girls with central precocious puberty treated with gonadotropin-releasing hormone analog
  7. The effect of GnRH stimulation on AMH regulation in central precocious puberty and isolated premature thelarche
  8. Association of the apoptotic marker APO1/Fas with children’s predisposing factors for metabolic syndrome and with mean platelet volume
  9. Serum adiponectin, body adiposity and metabolic parameters in obese Egyptian children with Down syndrome
  10. Urinary iodine and thyroglobulin are useful markers in infants suspected of congenital hypothyroidism based on newborn screening
  11. Comparison of plasmapheresis with medical apheresis in terms of efficacy and cost in the acute treatment of hypertriglyceridemia in children with lipoprotein lipase deficiency
  12. Clinical, biochemical and genotypical characteristics in biotinidase deficiency
  13. High uric acid levels in overweight and obese children and their relationship with cardiometabolic risk factors: what is missing in this puzzle?
  14. Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation
  15. Determinants of ultra-processed food consumption in Brazilian children and adolescents with type 1 diabetes mellitus: a cross-sectional study
  16. The prevalence, immune profile, and clinical characteristics of children with celiac disease and type 1 diabetes mellitus in the state of Qatar
  17. Case Reports
  18. A rare and preventable aetiology of neurodevelopmental delay and epilepsy: familial glucocorticoid deficiency
  19. Giant plurihormonal pituitary adenoma in a child – case study
  20. The usefulness of copeptin for the diagnosis of nephrogenic diabetes insipidus in infancy: a case report
  21. A novel synonymous homozygous variant [c.2538G>A (p.Thr846Thr)] in TRPM6 in a patient with hypomagnesemia with secondary hypocalcemia
  22. Idiopathic juvenile osteoporosis in a child: a four-year follow-up with review of literature
Heruntergeladen am 19.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2021-0094/pdf
Button zum nach oben scrollen